Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PTX 9908

Drug Profile

PTX 9908

Alternative Names: PTX-9908

Latest Information Update: 28 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pertinax Therapeutics
  • Class Antineoplastics; CXC chemokines; Peptides
  • Mechanism of Action CXCR4 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 07 Feb 2019 TCM Biotech International plans a phase I/II trial for Liver cancer (Inoperable/Unresectable) in Taiwan, in August 2019 (NCT03812874)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Cancer in Europe (IV, Infusion)
  • 26 Feb 2016 Phase-I/II development is ongoing in North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top